← Leaderboards
Michael A Rosenberg
Massachusetts General Hospital
$4,803,435
Attributed
$4,803,435
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $969.6K · FY2015–24$1M$750K$500K$250K$0
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$4,803,435 · 2
By mechanism
R01$3,871,023 · 1
K23$932,412 · 1
Top collaborators
No co-investigators on record.
Most similar at Massachusetts General Hospital
Same institution · by research overlap
- Christopher Holmes Newton-Cheh$8,878,611
- Sammy Elmariah$3,623,388
- Lidia Maria Veras Rocha De Moura$5,521,503
- David Eddie$1,573,594
- Bruce E Sands$6,502,130
Others in their field
Top investigators on “Insight”
- Sonia M Thomas · Research Triangle Institute$701,865,642
- Tracy L Nolen · Research Triangle Institute$474,487,152
- James Dennis Neaton · Northwestern University$283,212,546
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$278,513,775
- Chanza Baytop · Westat, Inc.$271,217,917
- Richard K. Wilson · Washington University$200,435,757
Research focus
InsightVariantInpatientsToxic EffectOutpatientsRestGenetic PredictorsGenetic EpidemiologyTorsades De PointesHospitalsInvestigationClinical ApplicationPharmaceutical PreparationsResponseDrug MarketElectronic Health RecordExcisionGeneticArrhythmiaGenetic RiskGenetic VariantGenotypeCardiotoxicityRisk Stratification
Grant awards (11)
Development of End-To-End Clinical Decision Support Tools To Prevent Cardiotoxic Drug Response$761,767
R01 · FY2024 · HL · contact PI
Development of End-To-End Clinical Decision Support Tools To Prevent Cardiotoxic Drug Response$777,314
R01 · FY2023 · HL · contact PI
Development of End-To-End Clinical Decision Support Tools To Prevent Cardiotoxic Drug Response$777,314
R01 · FY2022 · HL · contact PI
Development of End-To-End Clinical Decision Support Tools To Prevent Cardiotoxic Drug Response$777,314
R01 · FY2021 · HL · contact PI
Development of End-To-End Clinical Decision Support Tools To Prevent Cardiotoxic Drug Response$777,314
R01 · FY2020 · HL · contact PI
Genetics of Cardiotoxic Drug Response$192,240
K23 · FY2020 · HL · contact PI
Genetics of Cardiotoxic Drug Response$192,240
K23 · FY2019 · HL · contact PI
Genetics of Cardiotoxic Drug Response$192,240
K23 · FY2018 · HL · contact PI
Genetics of Cardiotoxic Drug Response$192,240
K23 · FY2016 · HL · contact PI
Genetics of Cardiotoxic Drug Response$5,646
K23 · FY2016 · HL · contact PI
Genetics of Cardiotoxic Drug Response$157,806
K23 · FY2015 · HL · contact PI